Abstract
Oncology drug development is an increasingly complex effort involving multiple stakeholders on a global scale. This review summarizes the role of the United States Food and Drug Administration (USFDA) and its office of oncology drugs in the regulation of anticancer drug therapies. The regulatory history of FDAs mission will be summarized. The FDAs role from first-in-human dose finding studies to trials designed to evaluate efficacy, as well as post-marketing considerations will be outlined. During this entire process, the FDA is committed to productive interactions with all its stakeholders, including the public, the pharmaceutical industry, academia, other government agencies and patient advocacy groups.
Keywords: investigational drug application (IND), post-marketing, new drug application (NDA), Clinical trials, Drug development
Current Cancer Therapy Reviews
Title: The Role of FDA in the Regulation of Anti-Cancer Drugs
Volume: 2 Issue: 4
Author(s): Ramzi N. Dagher and Richard Pazdur
Affiliation:
Keywords: investigational drug application (IND), post-marketing, new drug application (NDA), Clinical trials, Drug development
Abstract: Oncology drug development is an increasingly complex effort involving multiple stakeholders on a global scale. This review summarizes the role of the United States Food and Drug Administration (USFDA) and its office of oncology drugs in the regulation of anticancer drug therapies. The regulatory history of FDAs mission will be summarized. The FDAs role from first-in-human dose finding studies to trials designed to evaluate efficacy, as well as post-marketing considerations will be outlined. During this entire process, the FDA is committed to productive interactions with all its stakeholders, including the public, the pharmaceutical industry, academia, other government agencies and patient advocacy groups.
Export Options
About this article
Cite this article as:
Dagher N. Ramzi and Pazdur Richard, The Role of FDA in the Regulation of Anti-Cancer Drugs, Current Cancer Therapy Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339406778699196
DOI https://dx.doi.org/10.2174/157339406778699196 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Paclitaxel-tyroserleutide Conjugates Self-assembly into Nanocarrier for Drug Delivery
Letters in Drug Design & Discovery Bifunctional siRNA Containing Immunostimulatory Motif Enhances Protection Against Pandemic H1N1 Virus Infection
Current Gene Therapy Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Molecular Dynamics Guided Receptor Independent 4D QSAR Studies of Substituted Coumarins as Anticancer Agents
Current Computer-Aided Drug Design Inhibition of DNA Topoisomerases by a Series of Benzoxazoles and their Possible Metabolites
Letters in Drug Design & Discovery Recent Progress in Signal Transduction Research of the Angiotensin II Type-1 Receptor: Protein Kinases, Vascular Dysfunction and Structural Requirement
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Recent Patents on Anti-Cancer Drug Discovery C. elegans Genetic Networks Predict Roles for O-GlcNAc Cycling in Key Signaling Pathways
Current Signal Transduction Therapy Antiepileptic Drug Interactions - Principles and Clinical Implications
Current Neuropharmacology Meet Our Editorial Board Member
Current Cancer Drug Targets A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry Rheumatoid Arthritis: A Clinical Overview of New Diagnostic and Treatment Approaches
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Drug Targets Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Phytosterols: Perspectives in Human Nutrition and Clinical Therapy
Current Medicinal Chemistry Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors
Medicinal Chemistry Molecularly Imprinted Solid Phase Extraction Before Capillary Electrophoresis for the Analysis of Estrogens in Serum Samples
Current Analytical Chemistry